Indeed, the synergistic combination of RR-CDG (i.t., every 3 days) with a PD-L1 blockade (i.p.,100 μg) stimulated stronger antitumor responses than monotherapy in a head and neck squamous cell cancer (HNSCC) mouse model [149]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.